Your browser doesn't support javascript.
loading
Impact of the 18F-FDG-PET/MRI on Metastatic Staging in Patients with Hepatocellular Carcinoma: Initial Results from 104 Patients.
Vermersch, Mathilde; Mulé, Sébastien; Chalaye, Julia; Galletto Pregliasco, Athena; Emsen, Berivan; Amaddeo, Giuliana; Monnet, Aurélien; Stemmer, Alto; Baranes, Laurence; Laurent, Alexis; Leroy, Vincent; Itti, Emmanuel; Luciani, Alain.
Afiliación
  • Vermersch M; Medical Imaging Department, Henri Mondor Hospital, APHP, 94000 Créteil, France.
  • Mulé S; Institut Mondor de la Recherche Biomédicale (IMRB) Team 18, INSERM Unit 955, Henri Mondor Hospital, 94000 Créteil, France.
  • Chalaye J; Medical Imaging Department, Lille University Hospital, 59000 Lille, France.
  • Galletto Pregliasco A; Medical Imaging Department, Henri Mondor Hospital, APHP, 94000 Créteil, France.
  • Emsen B; Institut Mondor de la Recherche Biomédicale (IMRB) Team 18, INSERM Unit 955, Henri Mondor Hospital, 94000 Créteil, France.
  • Amaddeo G; Nuclear Medicine Department, Henri Mondor Hospital, APHP, 94000 Créteil, France.
  • Monnet A; Medical Imaging Department, Henri Mondor Hospital, APHP, 94000 Créteil, France.
  • Stemmer A; Nuclear Medicine Department, Henri Mondor Hospital, APHP, 94000 Créteil, France.
  • Baranes L; Department of Hepatogastroenterology, Henri Mondor Hospital, APHP, 94000 Créteil, France.
  • Laurent A; Siemens Healthineers, Siemens Healthcare GmbH, 91052 Erlangen, Germany.
  • Leroy V; Siemens Healthineers, Siemens Healthcare GmbH, 91052 Erlangen, Germany.
  • Itti E; Medical Imaging Department, Henri Mondor Hospital, APHP, 94000 Créteil, France.
  • Luciani A; Hepatobiliary Surgery and Liver Transplantation, Henri Mondor Hospital, APHP, 94000 Créteil, France.
J Clin Med ; 10(17)2021 Sep 06.
Article en En | MEDLINE | ID: mdl-34501465
Optimal HCC therapeutic management relies on accurate tumor staging. Our aim was to assess the impact of 18F-FDG-WB-PET/MRI on HCC metastatic staging, compared with the standard of care CT-CAP/liver MRI combination, in patients with HCC referred on a curative intent or before transarterial radioembolization. One hundred and four consecutive patients followed for HCC were retrospectively included. The WB-PET/MRI was compared with the standard of care CT-CAP/liver MRI combination for HCC metastatic staging, with pathology, followup, and multidisciplinary board assessment as a reference standard. Thirty metastases were identified within 14 metastatic sites in 11 patients. The sensitivity of WB-PET/MRI for metastatic sites and metastatic patients was significantly higher than that of the CT-CAP/liver MRI combination (respectively 100% vs. 43%, p = 0.002; and 100% vs. 45%, p = 0.01). Metastatic sites missed by CT-CAP were bone (n = 5) and distant lymph node (n = 3) in BCLC C patients. For the remaining 93 nonmetastatic patients, three BCLC A patients identified as potentially metastatic on the CT-CAP/liver MRI combination were correctly ruled out with the WB-PET/MRI without significant increase in specificity (100% vs. 97%; p = 0.25). The WB-PET/MRI may improve HCC metastatic staging and could be performed as a "one-stop-shop" examination for HCC staging with a significant impact on therapeutic management in about 10% of patients especially in locally advanced HCC.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Clin Med Año: 2021 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Clin Med Año: 2021 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Suiza